Dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK) (DYRK)

Dual-specificity tyrosine-phosphorylation-regulated kinases (DYRKs) are a family of evolutionarily conserved protein kinases that play critical roles in cell proliferation, differentiation, and survival (Source: UniProt). They are characterized by a unique 'dual-specificity' mechanism where they autophosphorylate a conserved tyrosine residue in their activation loop during translation to become active, but subsequently function as proline-directed serine/threonine kinases toward their substrates (Source: PubMed, PMID: 25830409). The family consists of five mammalian members (DYRK1A, 1B, 2, 3, and 4), with DYRK1A being the most extensively studied due to its localization in the Down Syndrome Critical Region on chromosome 21 (Source: NIH). Overexpression of DYRK1A is a major contributor to cognitive impairment in Down syndrome and is heavily implicated in Alzheimer's disease through the hyperphosphorylation of tau protein and the promotion of amyloid-beta production (Source: PubMed, PMID: 30639188). Beyond neurodegeneration, DYRKs are involved in cancer progression, where they can act as either oncogenes or tumor suppressors, and in diabetes, where they regulate pancreatic beta-cell proliferation (Source: Nature Communications). Current drug development efforts focus on small-molecule inhibitors like CX-4945 and Lorecivivint to modulate these pathways for therapeutic benefit in oncology and regenerative medicine (Source: ClinicalTrials.gov).

Other names

MNBMinibrainDual-specificity tyrosine-(Y)-phosphorylation regulated kinaseDYRK1ADYRK1BDYRK2DYRK3DYRK4

ATP-competitive inhibition of the kinase domain to prevent phosphorylation of downstream substrates such as Tau, NFAT, and MAP1B (Source: PubMed, PMID: 25830409).